Clinical Phenotype and Outcomes of Multisystem Inflammatory Syndrome in Children According to SARS‐CoV‐2 Laboratory Status During 2020–2021: A Retrospective Observational Study
Open Access
- 5 November 2026
- journal article
- Published by Wiley in Health Science Reports
- Vol. 9 (11)
Abstract
Background and Aims: Multisystem inflammatory syndrome in children (MIS‐C) is a post‐infectious inflammatory condition associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) that can affect multiple organ systems. Data comparing clinical features and outcomes between MIS‐C patients with and without laboratory evidence of coronavirus disease 2019 (COVID‐19) remain limited. Methods: This retrospective observational study was conducted at Mofid Children's Hospital, a pediatric referral center in Tehran, Iran, between March 2020 and July 2021. Children diagnosed with MIS‐C based on World Health Organization (WHO) criteria were included and classified into groups with and without laboratory evidence of SARS‐CoV‐2 infection according to PCR and/or IgG serology results. Demographic data, clinical manifestations, laboratory and imaging findings, treatments, and outcomes were compared between the groups using univariate and multivariable analyses. A p ‐value < 0.05 was considered statistically significant. Results: A total of 121 patients with MIS‐C were included, of whom 44 (36.4%) had laboratory evidence of SARS‐CoV‐2 infection. The mean age was 4.74 ± 3.99 years, and 61.2% were male. ICU admission occurred in 21.5% and mortality was 2.5%. In univariate analysis, fever during the first 24 h of hospitalization and antiviral use were more frequent in the group with laboratory evidence, whereas conjunctivitis and elevated C‐reactive protein levels were more common among the group without laboratory evidence; however, CRP did not differ significantly between groups when analyzed as a continuous variable. In multivariable analysis, fever during the first 24 h of hospitalization was the only variable associated with laboratory evidence of SARS‐CoV‐2 infection (aOR 2.57; 95% CI 1.05–6.30; p = 0.040). Conclusion: MIS‐C presents with broad and largely overlapping clinical, laboratory, and imaging features regardless of SARS‐CoV‐2 laboratory status, and the few observed differences were exploratory and of limited discriminative value. These findings highlight the importance of considering MIS‐C even in the absence of laboratory confirmation of SARS‐CoV‐2 infection.Keywords
This publication has 37 references indexed in Scilit:
- Systematic review and meta‐analysis on the serological, immunological, and cardiac parameters of the multisystem inflammatory syndrome (MIS‐C) associated with SARS‐CoV‐2 infectionJournal of Medical Virology, 2023
- Emerging Insights Into the Pathophysiology of Multisystem Inflammatory Syndrome Associated With COVID-19 in ChildrenCanadian Journal of Cardiology, 2023
- Imaging findings in acute pediatric coronavirus disease 2019 (COVID-19) pneumonia and multisystem inflammatory syndrome in children (MIS-C)Pediatric Radiology, 2022
- Clinical features and outcome of MIS-C patients: an experience from Central AnatoliaClinical Rheumatology, 2021
- The inflammatory markers of multisystem inflammatory syndrome in children (MIS‐C) and adolescents associated with COVID‐19: A meta‐analysisJournal of Medical Virology, 2021
- Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19JAMA, 2021
- Race/Ethnicity Among Children With COVID-19–Associated Multisystem Inflammatory SyndromeJAMA Network Open, 2020
- Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2JAMA, 2020
- Clinical characteristics of a case series of children with coronavirus disease 2019Pediatric Pulmonology, 2020
- Applied Logistic Regression2013